



Clinical trial results:

Estudio de fase IIIB, abierto, multinacional, aleatorizado y controlado para demostrar la no inferioridad de la respuesta inmunitaria a la vacuna antimeningocócica (serogrupos A, C, W-135 e Y) conjugada (MenACWY-TT) de GSK Biologicals, administrada por vía intramuscular a los 2, 4 y 12 meses de edad o a los 2, 3, 4 y 12 meses de edad, en comparación con dos vacunas MenC conjugadas y autorizadas, administradas por vía intramuscular a los 2, 4 y 12 meses de edad.

Summary

EudraCT number	2009-016841-24
Trial protocol	ES DE EE
Global end of trial date	10 September 2013

Results information

Result version number	v1
This version publication date	22 April 2016
First version publication date	05 June 2015

Trial information

Trial identification

Sponsor protocol code	113369
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01144663
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000429-PIP01-08
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 June 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 June 2012
Global end of trial reached?	Yes
Global end of trial date	10 September 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Demostrar, a los 5 meses de edad:

- 1.la no inferioridad del esquema de 3 dosis de la vacuna MenACWY-TT conjugada en comparación con el esquema de 2 dosis de la vacuna MenC-CRM197 conjugada
- 2.la no inferioridad del esquema de 3 dosis de la vacuna MenACWY-TT conjugada, frente al esquema de 2 dosis de la vacuna MenC-TT conjugada
- 3.la no inferioridad del esquema de 2 dosis de la vacuna MenACWY-TT conjugada frente al esquema de 2 dosis de la vacuna MenC-CRM197 conjugada
- 4.la no inferioridad del esquema de 2 dosis de la vacuna MenACWY-TT conjugada, frente al esquema de 2 dosis de la vacuna MenC-TT conjugada

Protection of trial subjects:

All subjects were supervised for 30 min after vaccination/product administration with appropriate medical treatment readily available. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for 30 days after the last vaccination/product administration.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 July 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	12 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Estonia: 34
Country: Number of subjects enrolled	Spain: 1559
Country: Number of subjects enrolled	Germany: 502
Worldwide total number of subjects	2095
EEA total number of subjects	2095

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	2095
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

Period 1 title	Primary Vaccination
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	GSK134612A 3-dose Group

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Nimenrix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2, 3 and 4 months of age and 1 booster dose at 12 months of age.

Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

Arm title	GSK134612A 2-dose Group
Arm description: -	
Arm type	Experimental

Investigational medicinal product name	Nimenrix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.	
Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 4 and 12 months of age.	
Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 4 and 12 months of age.	
Arm title	Menjugate Group
Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	Menjugate®
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.	
Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 4 and 12 months of age.	
Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 4 and 12 months of age.	
Arm title	NeisVac-C Group
Arm description: -	
Arm type	Active comparator

Investigational medicinal product name	NeisVac-CTM
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.

Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

Number of subjects in period 1	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group
Started	528	524	516
Completed	508	517	508
Not completed	20	7	8
Other (please specify)	20	7	8

Number of subjects in period 1	NeisVac-C Group
Started	527
Completed	509
Not completed	18
Other (please specify)	18

Period 2

Period 2 title	Booster Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	GSK134612A 3-dose Group
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Nimenrix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2, 3 and 4 months of age and 1 booster dose at 12 months of age.

Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2, 3, 4 and 12 months of age.

Arm title	GSK134612A 2-dose Group
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Nimenrix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.

Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

Arm title	Menjugate Group
Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	Menjugate®
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.	
Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 4 and 12 months of age.	
Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 4 and 12 months of age.	
Arm title	NeisVac-C Group
Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	NeisVac-CTM
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 and 4 months of age and 1 booster dose at 12 months of age.	
Investigational medicinal product name	Infanrix™ hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
Single dose intramuscular injection at 2 4 and 12 months of age.	
Investigational medicinal product name	Synflorix™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Single dose intramuscular injection at 2 4 and 12 months of age.

Number of subjects in period 2^[1]	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group
Started	497	511	503
Completed	494	509	498
Not completed	3	2	5
Consent withdrawn by subject	-	-	1
Migrated/moved from study area	1	1	1
Lost to follow-up	2	1	3

Number of subjects in period 2^[1]	NeisVac-C Group
Started	506
Completed	505
Not completed	1
Consent withdrawn by subject	1
Migrated/moved from study area	-
Lost to follow-up	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Subjects not returning for a specific visit were not withdrawn and could participate in the subsequent follow-up study. Actual enrolment differed depending on the rate of return for the follow-up study, so not all enrolled subjects came to each visit.

Baseline characteristics

Reporting groups

Reporting group title	GSK134612A 3-dose Group
Reporting group description: -	
Reporting group title	GSK134612A 2-dose Group
Reporting group description: -	
Reporting group title	Menjugate Group
Reporting group description: -	
Reporting group title	NeisVac-C Group
Reporting group description: -	

Reporting group values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group
Number of subjects	528	524	516
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: weeks			
arithmetic mean standard deviation	8.7 ± 1.54	8.6 ± 1.52	8.7 ± 1.53
Gender categorical Units: Subjects			
Female	255	273	264
Male	273	251	252

Reporting group values	NeisVac-C Group	Total	
Number of subjects	527	2095	
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years		0 0 0 0 0 0 0	

85 years and over		0	
-------------------	--	---	--

Age continuous			
Units: weeks			
arithmetic mean	8.6		
standard deviation	± 1.49	-	
Gender categorical			
Units: Subjects			
Female	251	1043	
Male	276	1052	

End points

End points reporting groups

Reporting group title	GSK134612A 3-dose Group
Reporting group description: -	
Reporting group title	GSK134612A 2-dose Group
Reporting group description: -	
Reporting group title	Menjugate Group
Reporting group description: -	
Reporting group title	NeisVac-C Group
Reporting group description: -	
Reporting group title	GSK134612A 3-dose Group
Reporting group description: -	
Reporting group title	GSK134612A 2-dose Group
Reporting group description: -	
Reporting group title	Menjugate Group
Reporting group description: -	
Reporting group title	NeisVac-C Group
Reporting group description: -	

Primary: Number of subjects with meningococcal polysaccharide C serum bactericidal assay, using baby rabbit complement (rSBA-MenC) titres $\geq 1:8$

End point title	Number of subjects with meningococcal polysaccharide C serum bactericidal assay, using baby rabbit complement (rSBA-MenC) titres $\geq 1:8$ ^[1]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

One month after vaccination.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[2]	0 ^[3]	0 ^[4]	0 ^[5]
Units: Subjects				

Notes:

[2] - These results were not available at the time of posting. The record will be updated.

[3] - These results were not available at the time of posting. The record will be updated.

[4] - These results were not available at the time of posting. The record will be updated.

[5] - These results were not available at the time of posting. The record will be updated.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom.

End point title	Number of subjects reporting any and grade 3 solicited local symptom.
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	518	523	509	518
Units: Subjects				
Any Pain, D1 (N=518; 523; 509; 517)	247	243	243	233
Grade 3 Pain, D1 (N=518; 523; 509; 517)	32	33	28	34
Any Redness, D1 (N=518; 523; 509; 517)	241	229	236	230
Grade 3 Redness, D1 (N=518; 523; 509; 517)	9	5	9	5
Any Swelling, D1 (N=518; 523; 509; 517)	188	182	179	188
Grade 3 Swelling, D1 (N=518; 523; 509; 517)	6	4	14	6
Any Pain, D2 (N=511; 517; 509; 513)	212	210	230	214
Grade 3 Pain, D2 (N=511; 517; 509; 513)	23	37	23	29
Any Redness, D2 (N=511; 517; 509; 513)	261	271	283	284
Grade 3 Redness, D2 (N=511; 517; 509; 513)	3	5	10	2
Any Swelling, D2 (N=511; 517; 509; 513)	211	206	225	210
Grade 3 Swelling, D2 (N=511; 517; 509; 513)	3	6	14	10
Any Pain, D3 (N=505; 517; 507; 508)	168	180	180	193
Grade 3 Pain, D3 (N=505; 517; 507; 508)	13	18	15	22
Any Redness, D3 (N=505; 517; 507; 508)	247	265	308	274
Grade 3 Redness, D3 (N=505; 517; 507; 508)	9	6	13	9
Any Swelling, D3 (N=505; 517; 507; 508)	210	216	252	218
Grade 3 Swelling, D3 (N=505; 517; 507; 508)	8	6	11	13
Any Pain, Overall (N=518; 523; 509; 518)	319	332	344	327
Grade 3 Pain, Overall (N=518; 523; 509; 518)	54	67	48	69
Any Redness, Overall (N=518; 523; 509; 518)	363	369	391	371
Grade 3 Redness, Overall (N=518; 523; 509; 518)	18	15	24	15

Any Swelling, Overall (N=518; 523; 509; 518)	326	318	343	317
Grade 3 Swelling, Overall (N=518; 523; 509; 518)	15	11	27	24

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination.

End point title	Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination.
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	518	523	509	518
Units: Subjects				
Any Pain, D1 (N=518; 523; 509; 517)	161	155	158	157
Grade 3 Pain, D1 (N=518; 523; 509; 517)	18	17	12	24
Any Redness, D1 (N=518; 523; 509; 517)	132	128	138	140
Grade 3 Redness, D1 (N=518; 523; 509; 517)	2	1	2	1
Any Swelling, D1 (N=518; 523; 509; 517)	68	62	87	82
Grade 3 Swelling, D1 (N=518; 523; 509; 517)	1	0	3	0
Any Pain, D2 (N=510; 0; 0; 0)	125	0	0	0
Grade 3 Pain, D2 (N=510; 0; 0; 0)	9	0	0	0
Any Redness, D2 (N=510; 0; 0; 0)	131	0	0	0
Grade 3 Redness, D2 (N=510; 0; 0; 0)	0	0	0	0
Any Swelling, D2 (N=510; 0; 0; 0)	77	0	0	0
Grade 3 Swelling, D2 (N=510; 0; 0; 0)	0	0	0	0
Any Pain, D3 (N=505; 516; 507; 508)	106	124	130	143
Grade 3 Pain, D3 (N=505; 516; 507; 508)	7	11	9	12
Any Redness, D3 (N=505; 516; 507; 508)	162	169	214	197
Grade 3 Redness, D3 (N=505; 516; 507; 508)	0	0	0	1
Any Swelling, D3 (N=505; 516; 507; 508)	104	115	137	130

Grade 3 Swelling, D3 (N=505; 516; 507; 508)	0	1	0	4
Any Pain, Overall (N=518; 523; 509; 518)	229	202	213	213
Grade 3 Pain, Overall (N=518; 523; 509; 518)	29	26	19	33
Any Redness, Overall (N=518; 523; 509; 518)	233	206	255	233
Grade 3 Redness, Overall (N=518; 523; 509; 518)	2	1	2	2
Any Swelling, Overall (N=518; 523; 509; 518)	154	136	175	164
Grade 3 Swelling, Overall (N=518; 523; 509; 518)	1	1	3	4

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa.

End point title	Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa.
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	518	523	509	517
Units: Subjects				
Any Pain, D1 (N=518; 523; 509; 517)	212	202	208	210
Grade 3 Pain, D1 (N=518; 523; 509; 517)	28	28	25	32
Any Redness, D1 (N=518; 523; 509; 517)	201	190	191	192
Grade 3 Redness, D1 (N=518; 523; 509; 517)	7	3	6	2
Any Swelling, D1 (N=518; 523; 509; 517)	148	148	128	147
Grade 3 Swelling, D1 (N=518; 523; 509; 517)	6	4	13	4
Any Pain, D2 (N=511; 517; 509; 513)	184	200	219	198
Grade 3 Pain, D2 (N=511; 517; 509; 513)	18	34	22	27
Any Redness, D2 (N=511; 517; 509; 513)	232	250	264	265
Grade 3 Redness, D2 (N=511; 517; 509; 513)	1	5	10	2

Any Swelling, D2 (N=511; 517; 509; 513)	182	185	208	195
Grade 3 Swelling, D2 (N=511; 517; 509; 513)	1	3	13	10
Any Pain, D3 (N=505; 517; 507; 508)	144	159	153	175
Grade 3 Pain, D3 (N=505; 517; 507; 508)	9	14	11	19
Any Redness, D3 (N=505; 517; 507; 508)	228	243	272	247
Grade 3 Redness, D3 (N=505; 517; 507; 508)	5	4	11	7
Any Swelling, D3 (N=505; 517; 507; 508)	191	200	227	197
Grade 3 Swelling, D3 (N=505; 517; 507; 508)	6	4	11	11
Any Pain, Overall (N=518; 523; 509; 518)	289	311	314	310
Grade 3 Pain, Overall (N=518; 523; 509; 518)	44	58	43	63
Any Redness, Overall (N=518; 523; 509; 518)	336	344	358	349
Grade 3 Redness, Overall (N=518; 523; 509; 518)	13	11	19	10
Any Swelling, Overall (N=518; 523; 509; 518)	297	292	308	294
Grade 3 Swelling, Overall (N=518; 523; 509; 518)	12	7	25	21

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix.

End point title	Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix.
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	518	523	509	518
Units: Subjects				
Any Pain, D1 (N=518; 523; 509; 517)	218	201	217	195
Grade 3 Pain, D1 (N=518; 523; 509; 517)	29	26	26	32
Any Redness, D1 (N=518; 523; 509; 517)	209	184	196	183

Grade 3 Redness, D1 (N=518; 523; 509; 517)	4	2	5	4
Any Swelling, D1 (N=518; 523; 509; 517)	135	136	130	120
Grade 3 Swelling, D1 (N=518; 523; 509; 517)	4	1	10	4
Any Pain, D2 (N=511; 517; 509; 513)	179	186	203	189
Grade 3 Pain, D2 (N=511; 517; 509; 513)	20	31	19	25
Any Redness, D2 (N=511; 517; 509; 513)	197	216	225	235
Grade 3 Redness, D2 (N=511; 517; 509; 513)	2	1	5	1
Any Swelling, D2 (N=511; 517; 509; 513)	154	162	156	155
Grade 3 Swelling, D2 (N=511; 517; 509; 513)	3	4	8	5
Any Pain, D3 (N=505; 517; 507; 508)	129	152	132	150
Grade 3 Pain, D3 (N=505; 517; 507; 508)	10	13	10	18
Any Redness, D3 (N=505; 517; 507; 508)	173	213	227	209
Grade 3 Redness, D3 (N=505; 517; 507; 508)	4	4	6	2
Any Swelling, D3 (N=505; 517; 507; 508)	136	152	164	146
Grade 3 Swelling, D3 (N=505; 517; 507; 508)	3	4	6	5
Any Pain, Overall (N=518; 523; 509; 518)	285	304	312	291
Grade 3 Pain, Overall (N=518; 523; 509; 518)	46	54	41	61
Any Redness, Overall (N=518; 523; 509; 518)	297	322	331	316
Grade 3 Redness, Overall (N=518; 523; 509; 518)	8	7	12	7
Any Swelling, Overall (N=518; 523; 509; 518)	247	259	262	237
Grade 3 Swelling, Overall (N=518; 523; 509; 518)	9	7	16	13

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination.

End point title	Number of subjects reporting any and grade 3 solicited local symptom post meningococcal vaccination.
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	491	510	496	503
Units: Subjects				
Any Pain	191	203	203	181
Grade 3 Pain	24	23	31	18
Any Redness	186	221	213	228
Grade 3 Redness	3	6	5	4
Any Swelling	133	152	158	165
Grade 3 Swelling	1	2	2	5

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa.

End point title	Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Infanrix hexa.
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	491	510	495	504
Units: Subjects				
Any Pain	240	241	242	221
Grade 3 Pain	35	33	39	23
Any Redness	259	286	282	280
Grade 3 Redness	29	24	32	22
Any Swelling	212	226	244	240
Grade 3 Swelling	20	18	17	14

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix.

End point title	Number of subjects reporting any and grade 3 solicited local symptom post vaccination with Synflorix.
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	491	510	495	504
Units: Subjects				
Any Pain	212	215	227	205
Grade 3 Pain	36	33	33	26
Any Redness	219	243	242	251
Grade 3 Redness	14	9	20	9
Any Swelling	173	174	189	195
Grade 3 Swelling	5	5	4	10

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related solicited general symptom.

End point title	Number of subjects reporting any, grade 3 and related solicited general symptom.
-----------------	--

End point description:

Symptoms were abbreviated as follows: D=Drowsiness; I=Irritability/Fussiness; L=Loss of appetite ; T=Temperature, while vaccine doses were D1=Dose 1, D2 = Dose2, D3 = Dose 3 and Overall = Across doses.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after each primary vaccine dose.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	518	523	509	518
Units: Subjects				
Any D, D1 (N=518; 523; 508; 517)	298	282	285	297
Grade 3 D, D1 (N=518; 523; 508; 517)	22	22	17	34
Related D, D1 (N=518; 523; 508; 517)	163	167	163	178
Any I, D1 (N=518; 523; 508; 517)	329	337	355	364
Grade 3 I, D1 (N=518; 523; 508; 517)	54	41	45	54
Related I, D1 (N=518; 523; 508; 517)	199	206	213	235
Any L, D1 (N=518; 523; 508; 517)	188	208	196	219
Grade 3 L, D1 (N=518; 523; 508; 517)	12	11	9	8
Related L, D1 (N=518; 523; 508; 517)	95	106	111	117
Any T, D1 (N=518; 523; 508; 517)	166	162	170	183
Grade 3 T, D1 (N=518; 523; 508; 517)	0	0	0	0
Related T, D1 (N=518; 523; 508; 517)	128	119	122	144
Any D, D2 (N=511; 515; 509; 512)	232	210	231	211
Grade 3 D, D2 (N=511; 515; 509; 512)	20	20	17	12
Related D, D2 (N=511; 515; 509; 512)	133	123	137	132
Any I, D2 (N=511; 515; 509; 512)	328	312	319	320
Grade 3 I, D2 (N=511; 515; 509; 512)	52	35	44	48
Related I, D2 (N=511; 515; 509; 512)	208	198	194	212
Any L, D2 (N=511; 515; 509; 512)	164	185	183	179
Grade 3 L, D2 (N=511; 515; 509; 512)	10	6	6	7
Related L, D2 (N=511; 515; 509; 512)	95	103	93	106
Any T, D2 (N=511; 515; 509; 512)	146	145	158	144
Grade 3 T, D2 (N=511; 515; 509; 512)	1	0	1	1
Related T, D2 (N=511; 515; 509; 512)	107	105	116	110
Any D, D3 (N=505; 516; 505; 507)	181	194	197	193
Grade 3 D, D3 (N=505; 516; 505; 507)	21	7	13	14
Related D, D3 (N=505; 516; 505; 507)	112	115	109	112
Any I, D3 (N=505; 516; 505; 507)	259	279	271	262
Grade 3 I, D3 (N=505; 516; 505; 507)	37	30	32	39
Related I, D3 (N=505; 516; 505; 507)	165	178	164	174
Any L, D3 (N=505; 516; 505; 507)	149	176	159	154
Grade 3 L, D3 (N=505; 516; 505; 507)	14	11	10	9
Related L, D3 (N=505; 516; 505; 507)	88	94	83	90
Any T, D3 (N=505; 516; 505; 507)	106	127	112	114
Grade 3 T, D3 (N=505; 516; 505; 507)	0	2	2	1
Related T, D3 (N=505; 516; 505; 507)	71	88	79	89
Any D, Overall (N=518; 523; 509; 518)	376	365	370	377
Grade 3 D, Overall (N=518; 523; 509; 518)	45	41	40	47
Related D, Overall (N=518; 523; 509; 518)	235	231	235	237
Any I, Overall (N=518; 523; 509; 518)	419	436	439	441
Grade 3 I, Overall (N=518; 523; 509; 518)	109	83	86	104
Related I, Overall (N=518; 523; 509; 518)	302	304	311	325
Any L, Overall (N=518; 523; 509; 518)	295	325	307	312
Grade 3 L, Overall (N=518; 523; 509; 518)	28	23	22	22

Related L, Overall (N=518; 523; 509; 518)	180	194	186	182
Any T, Overall (N=518; 523; 509; 518)	272	274	277	275
Grade 3 T, Overall (N=518; 523; 509; 518)	1	2	3	2
Related T, Overall (N=518; 523; 509; 518)	203	208	208	220

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related solicited general symptom.

End point title	Number of subjects reporting any, grade 3 and related solicited general symptom.
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Within 8 days (days 0 to 7) after booster vaccination.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	491	510	496	504
Units: Subjects				
Any Drowsiness	198	206	208	202
Grade 3 Drowsiness	14	13	21	18
Related Drowsiness	125	129	119	125
Any Irritability	284	296	284	297
Grade 3 Irritability	41	37	37	45
Related Irritability	180	197	181	186
Any Loss of appetite	189	193	198	195
Grade 3 Loss of appetite	12	21	23	27
Related Loss of appetite	118	114	114	121
Any Temperature (Rectally)	187	180	186	170
Grade 3 Temperature (Rectally)	2	2	3	7
Related Temperature (Rectally)	133	132	122	125

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited adverse events (AEs).

End point title	Number of subjects reporting any unsolicited adverse events
-----------------	---

(AEs).

End point description:

End point type Secondary

End point timeframe:

Within 31 days (days 0 to 30) after each primary vaccine dose.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	528	524	516	527
Units: Subjects				
Any AE(s)	293	273	291	280

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited adverse events (AEs).

End point title Number of subjects reporting any unsolicited adverse events (AEs).

End point description:

End point type Secondary

End point timeframe:

Within 31 days (days 0 to 30) after booster vaccination.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	497	511	503	506
Units: Subjects				
Any AE(s)	179	185	164	167

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting serious adverse events (SAEs).

End point title Number of subjects reporting serious adverse events (SAEs).

End point description:

End point type	Secondary
End point timeframe:	
Throughout the entire primary study (Day 0 - Month 16).	

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	528	524	516	527
Units: Subjects				
Any SAE(s)	1	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting serious adverse events (SAEs).

End point title	Number of subjects reporting serious adverse events (SAEs).
End point description:	

End point type	Secondary
End point timeframe:	
Throughout the entire booster study.	

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	497	511	503	506
Units: Subjects				
Any SAE(s)	26	31	25	25

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs).

End point title	Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs).
End point description:	

End point type	Secondary
----------------	-----------

End point timeframe:

During the 31 days (Days 0-30) post-each primary vaccination dose.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	528	524	516	527
Units: Subjects				
Any NOCI(s)	11	6	5	5

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs).

End point title	Number of subjects reporting any specific AEs of new onset of chronic illnesses (NOCIs).
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From booster vaccination up to ESFU contact.

End point values	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group	NeisVac-C Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	497	511	503	506
Units: Subjects				
Any NOCI(s)	2	2	7	5

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

- Solicited local and general symptoms: during the 8 day - (Day 0-Day 7) after each vaccination
- Unsolicited adverse events: during the 31 day (Day 0 - Day 30) after each vaccination
- SAEs: throughout the entire study (Day 0 – Month 1)

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

Reporting groups

Reporting group title	GSK134612A 3-dose Group
-----------------------	-------------------------

Reporting group description: -	
--------------------------------	--

Reporting group title	GSK134612A 2-dose Group
-----------------------	-------------------------

Reporting group description: -	
--------------------------------	--

Reporting group title	Menjugate Group
-----------------------	-----------------

Reporting group description: -	
--------------------------------	--

Reporting group title	NeisVac-C Group
-----------------------	-----------------

Reporting group description: -	
--------------------------------	--

Serious adverse events	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group
Total subjects affected by serious adverse events			
subjects affected / exposed	54 / 528 (10.23%)	56 / 524 (10.69%)	45 / 516 (8.72%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cerebral haemangioma (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemangioma (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Kawasaki's disease (Booster)			

subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kawasaki's disease (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	5 / 524 (0.95%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Milk allergy (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Milk allergy (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Balanoposthitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular retraction (Booster)			

subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Balanoposthitis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular retraction (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchial hyperreactivity (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngospasm (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis allergic (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity (Primary)			

subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apparent life threatening event			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asphyxia			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchospasm (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngospasm (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis allergic (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breath holding			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Alanine aminotransferase increased subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	4 / 516 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn (Booster)			
subjects affected / exposed	2 / 528 (0.38%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Near drowning (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Concussion (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	4 / 516 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn (Primary)			
subjects affected / exposed	2 / 528 (0.38%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Near drowning (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Laryngomalacia			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Plagiocephaly			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Wolff-Parkinson-White syndrome			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Epilepsy (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain injury (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Brain injury (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotonia			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Conjunctivitis allergic (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctivitis allergic (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Vomiting (Booster)			
subjects affected / exposed	2 / 528 (0.38%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphthous stomatitis (Booster)			

subjects affected / exposed	0 / 528 (0.00%)	2 / 524 (0.38%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia, obstructive (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	3 / 524 (0.57%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting (Primary)			
subjects affected / exposed	2 / 528 (0.38%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphthous stomatitis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	2 / 524 (0.38%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			

subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia, obstructive (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Haematuria (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sacroiliitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Torticollis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle spasms (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sacroiliitis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Torticollis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis (Booster)			
subjects affected / exposed	5 / 528 (0.95%)	4 / 524 (0.76%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 5	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis (Booster)			
subjects affected / exposed	4 / 528 (0.76%)	2 / 524 (0.38%)	4 / 516 (0.78%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	2 / 524 (0.38%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	2 / 524 (0.38%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia (booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	3 / 516 (0.58%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media (Booster)			
subjects affected / exposed	3 / 528 (0.57%)	0 / 524 (0.00%)	2 / 516 (0.39%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	2 / 524 (0.38%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute (Booster)			

subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia (Booster)			

subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial pyelonephritis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctivitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctivitis bacterial (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exanthema subitum (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus (Booster)			

subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital candidiasis (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand-foot-and-mouth disease (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis (Booster)			

subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection (Booster)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral rash (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis (Primary)			

subjects affected / exposed	12 / 528 (2.27%)	10 / 524 (1.91%)	9 / 516 (1.74%)
occurrences causally related to treatment / all	0 / 12	0 / 10	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis (Primary)			
subjects affected / exposed	9 / 528 (1.70%)	4 / 524 (0.76%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 9	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis (Primary)			
subjects affected / exposed	6 / 528 (1.14%)	3 / 524 (0.57%)	5 / 516 (0.97%)
occurrences causally related to treatment / all	0 / 6	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia (Primary)			
subjects affected / exposed	3 / 528 (0.57%)	3 / 524 (0.57%)	2 / 516 (0.39%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection (Primary)			
subjects affected / exposed	4 / 528 (0.76%)	2 / 524 (0.38%)	2 / 516 (0.39%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus (Primary)			
subjects affected / exposed	2 / 528 (0.38%)	2 / 524 (0.38%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	1 / 524 (0.19%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	2 / 528 (0.38%)	3 / 524 (0.57%)	2 / 516 (0.39%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia (Primary)			

subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	4 / 516 (0.78%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media (Primary)			
subjects affected / exposed	3 / 528 (0.57%)	0 / 524 (0.00%)	2 / 516 (0.39%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection (Primary)			
subjects affected / exposed	3 / 528 (0.57%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctivitis (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	1 / 524 (0.19%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial pyelonephritis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	2 / 524 (0.38%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis (Primary)			

subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection (Primary)			
subjects affected / exposed	2 / 528 (0.38%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Conjunctivitis bacterial (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup infectious			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epstein-Barr virus infection			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exanthema subitum (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis bacterial (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus (Primary)			

subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Genital candidiasis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
H1N1 influenza			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand-foot-and-mouth disease (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	1 / 516 (0.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes (Primary)			

subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pertussis			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection (Primary)			

subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis (Primary)			
subjects affected / exposed	1 / 528 (0.19%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral rash (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	1 / 524 (0.19%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite (Booster)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite (Primary)			
subjects affected / exposed	0 / 528 (0.00%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	NeisVac-C Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	52 / 527 (9.87%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cerebral haemangioma (Booster)			

subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral haemangioma (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Kawasaki's disease (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Kawasaki's disease (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia (Primary)			
subjects affected / exposed	3 / 527 (0.57%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Milk allergy (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Milk allergy (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Reproductive system and breast disorders			
Balanoposthitis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular retraction (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Balanoposthitis (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular retraction (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchial hyperreactivity (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Asthma (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchospasm (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Laryngospasm (Booster)			

subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rhinitis allergic (Booster)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bronchial hyperreactivity (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Apparent life threatening event				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Asphyxia				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Asthma (Primary)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bronchospasm (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Laryngospasm (Primary)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rhinitis allergic (Primary)				

subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Concussion (Booster)			
subjects affected / exposed	2 / 527 (0.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Contusion (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thermal burn (Booster)			

subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Near drowning (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skull fracture (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Concussion (Primary)			
subjects affected / exposed	2 / 527 (0.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Contusion (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thermal burn (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Joint dislocation			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Near drowning (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Overdose			

subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skull fracture (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Laryngomalacia			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Plagiocephaly			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Wolff-Parkinson-White syndrome			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Epilepsy (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile convulsion (Booster)			
subjects affected / exposed	2 / 527 (0.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Epilepsy (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Brain injury (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile convulsion (Primary)			
subjects affected / exposed	2 / 527 (0.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Epilepsy			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Brain injury (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotonia			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Lymphadenitis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenitis (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Conjunctivitis allergic (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Conjunctivitis allergic (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Vomiting (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Aphthous stomatitis (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enteritis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia, obstructive (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enteritis (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Aphthous stomatitis (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematemesis			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia, obstructive (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Urticaria			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Haematuria (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthritis (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscle spasms (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sacroiliitis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Torticollis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscle spasms (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Arthritis (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sacroiliitis (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Torticollis (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bronchitis (Booster)			
subjects affected / exposed	4 / 527 (0.76%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis (Booster)			
subjects affected / exposed	2 / 527 (0.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia (Booster)			
subjects affected / exposed	3 / 527 (0.57%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis (Booster)			
subjects affected / exposed	2 / 527 (0.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bronchopneumonia (booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Otitis media (Booster)			

subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis rotavirus (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Otitis media acute (Booster)				
subjects affected / exposed	2 / 527 (0.38%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection (Booster)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Laryngitis (Booster)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Nasopharyngitis (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis (Booster)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Abscess (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Adenovirus infection (Booster)				

subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal abscess (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atypical pneumonia (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacterial pyelonephritis (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Conjunctivitis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Conjunctivitis bacterial (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalitis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Exanthema subitum (Booster)			

subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis bacterial (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis norovirus (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis salmonella (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Genital candidiasis (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hand-foot-and-mouth disease (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes simplex (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis (Booster)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung infection (Booster)				

subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oral herpes (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngitis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia bacterial (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis acute (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rotavirus infection (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tonsillitis (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral infection (Booster)			

subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral rash (Booster)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchiolitis (Primary)			
subjects affected / exposed	14 / 527 (2.66%)		
occurrences causally related to treatment / all	0 / 14		
deaths causally related to treatment / all	0 / 0		
Bronchitis (Primary)			
subjects affected / exposed	8 / 527 (1.52%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis (Primary)			
subjects affected / exposed	3 / 527 (0.57%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Pneumonia (Primary)			
subjects affected / exposed	4 / 527 (0.76%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis rotavirus (Primary)			
subjects affected / exposed	2 / 527 (0.38%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis (Primary)			

subjects affected / exposed	4 / 527 (0.76%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Respiratory syncytial virus bronchiolitis				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchopneumonia (Primary)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Otitis media (Primary)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection (Primary)				
subjects affected / exposed	2 / 527 (0.38%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Conjunctivitis (Primary)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bacterial pyelonephritis (Primary)				
subjects affected / exposed	2 / 527 (0.38%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Nasopharyngitis (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Otitis media acute (Primary)				

subjects affected / exposed	2 / 527 (0.38%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Laryngitis (Primary)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Oral candidiasis				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Viral infection (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abscess (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Adenovirus infection (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anal abscess (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atypical pneumonia (Primary)				

subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Conjunctivitis bacterial (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Croup infectious			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalitis (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epstein-Barr virus infection			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia urinary tract infection			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Exanthema subitum (Primary)			

subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis bacterial (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis norovirus (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis salmonella (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Genital candidiasis (Primary)				
subjects affected / exposed	1 / 527 (0.19%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
H1N1 influenza				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hand-foot-and-mouth disease (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes simplex (Primary)				
subjects affected / exposed	0 / 527 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis (Primary)				

subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung infection (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oral herpes (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteomyelitis			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pertussis			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pharyngitis (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia bacterial (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis acute			

subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rotavirus infection (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tonsillitis (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral rash (Primary)			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Decreased appetite (Booster)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Decreased appetite (Primary)			
subjects affected / exposed	1 / 527 (0.19%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	GSK134612A 3-dose Group	GSK134612A 2-dose Group	Menjugate Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	419 / 528 (79.36%)	436 / 524 (83.21%)	439 / 516 (85.08%)
General disorders and administration site conditions			
Pain			
alternative assessment type: Systematic			
subjects affected / exposed	319 / 528 (60.42%)	332 / 524 (63.36%)	344 / 516 (66.67%)
occurrences (all)	319	332	344
Redness			
alternative assessment type: Systematic			
subjects affected / exposed	363 / 528 (68.75%)	369 / 524 (70.42%)	391 / 516 (75.78%)
occurrences (all)	363	369	391
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed	326 / 528 (61.74%)	318 / 524 (60.69%)	343 / 516 (66.47%)
occurrences (all)	326	318	343
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed	376 / 528 (71.21%)	365 / 524 (69.66%)	370 / 516 (71.71%)
occurrences (all)	376	365	370
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed	419 / 528 (79.36%)	436 / 524 (83.21%)	439 / 516 (85.08%)
occurrences (all)	419	436	439
Loss of appetite			
alternative assessment type: Systematic			
subjects affected / exposed	295 / 528 (55.87%)	325 / 524 (62.02%)	307 / 516 (59.50%)
occurrences (all)	295	325	307
Temperature/(Rectally $\geq 38.0^{\circ}\text{C}$)			
alternative assessment type: Systematic			
subjects affected / exposed	272 / 528 (51.52%)	274 / 524 (52.29%)	277 / 516 (53.68%)
occurrences (all)	272	274	277

Respiratory, thoracic and mediastinal disorders			
Rhinitis			
subjects affected / exposed	32 / 528 (6.06%)	27 / 524 (5.15%)	33 / 516 (6.40%)
occurrences (all)	32	27	33
Infections and infestations			
Upper respiratory tract infection (post-primary)			
subjects affected / exposed	82 / 528 (15.53%)	86 / 524 (16.41%)	80 / 516 (15.50%)
occurrences (all)	82	86	80
Nasopharyngitis			
subjects affected / exposed	43 / 528 (8.14%)	34 / 524 (6.49%)	46 / 516 (8.91%)
occurrences (all)	43	34	46
Bronchiolitis			
subjects affected / exposed	41 / 528 (7.77%)	34 / 524 (6.49%)	33 / 516 (6.40%)
occurrences (all)	41	34	33
Bronchitis			
subjects affected / exposed	34 / 528 (6.44%)	0 / 524 (0.00%)	0 / 516 (0.00%)
occurrences (all)	34	0	0
Upper respiratory tract infection (post-booster)			
subjects affected / exposed	38 / 528 (7.20%)	54 / 524 (10.31%)	53 / 516 (10.27%)
occurrences (all)	38	54	53

Non-serious adverse events	NeisVac-C Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	441 / 527 (83.68%)		
General disorders and administration site conditions			
Pain			
alternative assessment type: Systematic			
subjects affected / exposed	327 / 527 (62.05%)		
occurrences (all)	327		
Redness			
alternative assessment type: Systematic			
subjects affected / exposed	371 / 527 (70.40%)		
occurrences (all)	371		
Swelling			
alternative assessment type: Systematic			

subjects affected / exposed	317 / 527 (60.15%)		
occurrences (all)	317		
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed	377 / 527 (71.54%)		
occurrences (all)	377		
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed	441 / 527 (83.68%)		
occurrences (all)	441		
Loss of appetite			
alternative assessment type: Systematic			
subjects affected / exposed	312 / 527 (59.20%)		
occurrences (all)	312		
Temperature/(Rectally $\geq 38.0^{\circ}\text{C}$)			
alternative assessment type: Systematic			
subjects affected / exposed	275 / 527 (52.18%)		
occurrences (all)	275		
Respiratory, thoracic and mediastinal disorders			
Rhinitis			
subjects affected / exposed	0 / 527 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Upper respiratory tract infection (post-primary)			
subjects affected / exposed	74 / 527 (14.04%)		
occurrences (all)	74		
Nasopharyngitis			
subjects affected / exposed	36 / 527 (6.83%)		
occurrences (all)	36		
Bronchiolitis			
subjects affected / exposed	44 / 527 (8.35%)		
occurrences (all)	44		
Bronchitis			

subjects affected / exposed	31 / 527 (5.88%)		
occurrences (all)	31		
Upper respiratory tract infection (post-booster)			
subjects affected / exposed	44 / 527 (8.35%)		
occurrences (all)	44		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 December 2010	<p>An inconsistency between inclusion criteria and Table 5 was noticed and Table 5 has been corrected according to inclusion criteria.</p> <p>The age for administration of the booster dose has been clarified.</p> <p>Procedure for reporting Guillain Barre syndrome (GBS) has been added.</p> <p>New cold chain deviation wording has been incorporated.</p>
25 May 2011	<p>The sample size of the study population is increased by approximately 50%, i.e., 680 additional subjects will be enrolled in the study to reach the target samples size of 1650 evaluable subjects to demonstrate the co-primary objectives of this study.</p> <p>The serum bactericidal assay (SBA) is a functional measure of the ability of antibodies in conjunction with complement to kill bacteria and is considered the assay of choice for measurement of functional anti-meningococcal antibodies in vitro. It is well known that, as there is no standardized SBA testing, the inter-laboratory variability could have an important impact on the measured bactericidal titers. Depending on the laboratory where the SBA testing is to be performed, differences around 1% in the percentage of subjects with seroprotective titers may occur. It has been estimated that 50% sample size increase would be necessary to demonstrate all the sequential co-primary objectives regardless of the laboratory where the testing is performed.</p> <p>The primary endpoint of the current study is to assess the immunogenicity induced by the components of the investigational vaccine in terms of rSBA titres $\geq 1:8$ for each of the four serogroups (A, C, W-135 and Y) in all subjects, one month after the final priming vaccination. In addition, rSBA titres $\geq 1:8$ and $\geq 1:128$ will also be assessed at any blood sampling time point during the study in a subset of subjects in all vaccine groups as secondary endpoints. To support the data obtained by rSBA testing, hSBA testing will also be performed and in addition antibody concentrations against meningococcal polysaccharides (PS) are planned to be assessed by ELISA (anti-PS testing). Now, GSK Biologicals decided not to perform anti-PS testing at any blood sampling time point for the following reasons:</p> <ul style="list-style-type: none">- the World Health Organization (WHO) considers SBA the primary means of assessing immune response to meningococcal conjugate vaccines [WHO, 2006; WHO, 1999].
30 July 2012	<p>A measles outbreak in Spain impacted 2 centers participating in the study and the local authorities recommended vaccinating subjects from 9 months old onwards. The protocol is amended to allow administration of Measles, Mumps, Rubella (MMR) or Measles, Mumps, Rubella and Varicella (MMRV) vaccine throughout the study in line with local governmental recommendations. It is preferable that the vaccine not be given within 30 days prior or after a dose of study vaccine (with the day of vaccination considered Day 0).</p> <p>The introduction was updated with the current licensing status of MenACWY-TT and competitor vaccines.</p> <p>Several sections were updated to clarify that the Immune Mediated Disease (IMD) report should only be used in case of Guillain-Barre syndrome (GBS).</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported